CARDIOMETABOLIC HEALTH

Interventions for Cardiovascular Risk Reduction in Type 2 Diabetes Must Be Multifactorial
Heart disease the leading cause of death in diabetic patients
By Wayne Kuznar  

Control of 4 Risk Factors Would Slash CHD Rate in Diabetes by Half

OBESITY/OVERWEIGHT

Belly Fat Triples CV and All-Cause Mortality, Even with Normal Weight
By Mary Mosley

EMERGING THERAPIES

CVD Pipeline: Novel Approaches to Modifying Lipids/Lipoproteins
A total of 16 new drug classes are in development

GLP-1 Agonism Holds Promise for Preventing Macrovascular Disease in Type 2 Diabetes

CVD MANAGEMENT

Third Definition of Myocardial Infarction Presented at ESC 2012, Focusing on New High-Sensitivity Biomarkers

HYPERTENSION

New Hypertension Guidelines Will Be Strictly Evidence-Based
In addition to skipping doses, many patients self-treat a hypoglycemic event

LIPID MANAGEMENT

Lipid Therapy Update: HDL Therapies Falling Short, Promising LDL Agents, 2 Potential Treatments for Familial Hypercholesterolemia

DRUG UPDATE

Belviq: A New Prescription Weight-Loss Treatment for Overweight or Obese Patients
By Loretta Fala

Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients

WEB EXCLUSIVE

• Probiotic Reduces LDL Cholesterol Level
• Not All Omega-3 Fatty Acids Have the Same Effects on Lipids
• Hypertension: Highlights from ESC 2012
• Impact of Healthy Lifestyle on Developing Hypertension Quantified
• Aspirin Safely Omitted from Antithrombotic Therapy in Patients with AF Undergoing PCI

View more articles here.